- Lexaria Bioscience is preparing to file an Investigational New Drug application with the U.S. Food and Drug Administration for its patented technology’s use in treating hypertension (high blood pressure)
- The company has completed multiple studies of the benefits of DehydraTECH(TM), in combination with cannabidiol to combat hypertension conditions and consequentially benefit cardiovascular patients
- Lexaria recently announced that it is nearing completion of a third human study in which the company expects to further explore whether DehydraTECH-CBD successfully treats high pulmonary blood pressure
- A comprehensive six-week human clinical study is expected to begin soon
Lexaria Bioscience (NASDAQ: LEXX) is nearing completion of a human clinical study it believes will further its claims that its patented DehydraTECH(TM) technology works effectively with cannabidiol (“CBD”) as a potential treatment for hypertension, which has further potential implications for cardiovascular disease patients.
Lexaria’s DehydraTECH technology works with drug substances which are orally ingested and enhances how they are processed into the blood stream without adverse consequences from the transformation process.
The company is continuing to generate positive test data through clinical trials as it works toward an Investigational New Drug (“IND”) application filing with the Food and Drug Administration (“FDA”) (https://ibn.fm/jHXZg).
The recently completed human clinical study HYPER-H21-3 enrolled 16 volunteers to study acute pulmonary hypertension, administering a single 300 mg dose of a specific DehydraTECH 2.0 CBD formulation to some of them and comparing their results to placebo performance in the remainder of the volunteers.
The study has collected blood samples from the volunteers for analysis and expects to report its findings on blood pressure response soon.
In cardiovascular conditions, hypertension, or high blood pressure, can lead to an excess of fluid in the lungs that causes difficulty with breathing when acute reductions in oxygen tension known as hypoxia lead pulmonary blood vessels to constrict and arterial pressure to increase.
Lexaria’s announcement notes that CBD’s potential as a novel treatment for the pulmonary blood vessel constriction and, as a consequence, for high pulmonary blood pressure has not been explored sufficiently. HYPER-H21-3 evaluates the effects of exposure to hypoxia on the volunteers treated alternatively with placebo or the DehydraTECH 2.0 CBD formulation.
The human study joins two others completed this year despite pandemic condition obstacles. The first noted that some hypertensive volunteers achieved a marked drop in blood pressure when administered a DehydraTECH-CBD formulation, in comparison to a control group using generic CBD as a placebo (https://ibn.fm/m8KwR). The second study found DehydraTECH-formulated CBD reduced arterial stiffness in mild-to-moderate hypertension patients in a blinded, placebo-controlled group (https://ibn.fm/ni2c9).
A fourth human study, HYPER-H21-4, will evaluate DehydraTECH-CBD as a treatment for hypertension and arterial stiffness over a six-week period.
Arterial stiffness naturally increases with age and is associated with increased mortality from diseases such as diabetes mellitus and kidney disorders, as well as the cardiovascular diseases that are the leading cause of death worldwide (https://ibn.fm/7mOQL). Dr. Vernon V S Bonarjee, the head of the cardiology department at Norway’s Stavanger University Hospital, has noted that measuring arterial stiffness may serve as a predictive indicator for determining treatment for cardiovascular disease, even among otherwise asymptomatic individuals, demonstrating the condition’s significance (https://ibn.fm/X3yzJ).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.